Literature DB >> 1560463

Antibody framework residues affecting the conformation of the hypervariable loops.

J Foote1, G Winter.   

Abstract

Rodent monoclonal antibodies have been "humanized" or "reshaped" for therapy by transplanting the antigen-binding loops from their variable domains onto the beta-sheet framework regions of human antibodies. However, additional substitutions in the human framework regions are sometimes required for high affinity antigen binding. Here we describe antigen binding by a reshaped antibody derived from the mouse anti-lysozyme antibody D1.3, and several variants in which point mutations had been introduced into framework positions to improve its affinity. The affinities were determined from the relaxation kinetics of reactant mixtures using quenching of fluorescence that occurs upon formation of the antibody-antigen complex. The dissociation constant of lysozyme ranged from 3.7 nM (for D1.3) to 260 nM. Measurement of antibody-antigen association kinetics using stopped-flow showed that D1.3 and most of the reshaped antibodies had bimolecular rate constants of 1.4 x 10(6) s-1 M-1, indicating that differences in equilibrium constant were predominantly due to different rates of dissociation of lysozyme from immune complexes. Mutations in a triad of heavy chain residues, 27, 29 and 71, contributed 0.9 kcal/mol in antigen binding free energy, and a Phe to Tyr substitution of light chain residue 71 contributed an additional 0.8 kcal/mol. The combined effect of all these mutations brought the affinity of the reshaped antibody to within a factor of 4 of D1.3. All of these substitutions were in the beta-sheet framework closely underlying the complementarity-determining regions, and do not participate in a direct interaction with antigen. The informed selection of residues in such positions may prove essential for the success of loop transplants in antibodies. Variation of these sites may also have a role in shaping the diversity of structures found in the primary repertoire, and in affinity maturation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560463     DOI: 10.1016/0022-2836(92)91010-m

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  117 in total

1.  N-terminal mutations in the anti-estradiol Fab 57-2 modify its hapten binding properties.

Authors:  P Saviranta PJauria; U Lamminmäki; J Hellman; S Eriksson; T Lövgren
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

2.  Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.

Authors:  E T Boder; K S Midelfort; K D Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

3.  Immunochemical pulsed-labeling characterization of intermediates during hen lysozyme oxidative folding.

Authors:  Nicole M Jarrett; Lisa Djavadi-Ohaniance; Richard C Willson; Hideki Tachibana; Michel E Goldberg
Journal:  Protein Sci       Date:  2002-11       Impact factor: 6.725

4.  Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level.

Authors:  Raimund J Ober; Cruz Martinez; Xuming Lai; Jinchun Zhou; E Sally Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-16       Impact factor: 11.205

5.  Antibody humanization by structure-based computational protein design.

Authors:  Yoonjoo Choi; Casey Hua; Charles L Sentman; Margaret E Ackerman; Chris Bailey-Kellogg
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

6.  Construction of human naïve Fab library and characterization of anti-met Fab fragment generated from the library.

Authors:  Yongjun Jiao; Ping Zhao; Jin Zhu; Tessa Grabinski; Zhengqing Feng; Xiaohong Guan; R Scot Skinner; Milton D Gross; Rick V Hay; Hiroshi Tachibana; Brian Cao
Journal:  Mol Biotechnol       Date:  2005-09       Impact factor: 2.695

7.  Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.

Authors:  Kannika Khantasup; Warangkana Chantima; Chak Sangma; Kanokwan Poomputsa; Tararaj Dharakul
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-12

8.  Novel Antibody for the Treatment of Transthyretin Amyloidosis.

Authors:  Akihiko Hosoi; Yu Su; Masaharu Torikai; Hirofumi Jono; Daisuke Ishikawa; Kenji Soejima; Hirofumi Higuchi; Jianying Guo; Mitsuharu Ueda; Genki Suenaga; Hiroaki Motokawa; Tokunori Ikeda; Satoru Senju; Toshihiro Nakashima; Yukio Ando
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

9.  Germline humanization of a murine Abeta antibody and crystal structure of the humanized recombinant Fab fragment.

Authors:  Remy Robert; Victor A Streltsov; Janet Newman; Lesley A Pearce; Kim L Wark; Olan Dolezal
Journal:  Protein Sci       Date:  2010-02       Impact factor: 6.725

10.  Isolation of human monoclonal antibodies by mammalian cell display.

Authors:  Roger R Beerli; Monika Bauer; Regula B Buser; Myriam Gwerder; Simone Muntwiler; Patrik Maurer; Philippe Saudan; Martin F Bachmann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.